This clinical trial aims to understand whether taurine can prevent and reduce severe radiation-induced oral mucositis in patients with nasopharyngeal carcinoma undergoing radiotherapy.
Age 18-70 years.
Histologically confirmed newly diagnosed non-keratinizing nasopharyngeal carcinoma (WHO classification).
Non-metastatic nasopharyngeal carcinoma (Stage I-III) according to the AJCC 9th edition staging system.
Scheduled to receive radical intensity-modulated radiotherapy (IMRT).
Known intolerance or hypersensitivity to taurine or its excipients.
Conditions that interfere with oral drug administration (e.g., dysphagia, chronic diarrhea, intestinal obstruction).
Prior history of malignant tumor.
Pregnant or lactating women. (Pregnancy testing is required for women of childbearing potential; effective contraception must be used during treatment.)